Genetic Tests
Factor V Leiden Mutation: What It Is and What It Means
The most common inherited thrombophilia worldwide. What does carrier status mean, heterozygous vs homozygous difference and how is it tested?
8 min · 5 March 2025
Factor V Leiden (FVL) is a G→A change at position 1691 of the gene coding the Factor V clotting protein (G1691A). This single nucleotide change converts the 506th amino acid of Factor V from arginine to glutamine (R506Q). The result: Protein C cannot degrade activated Factor V — the clot survives longer than normal.
Why So Common?
Heterozygous FVL carriage occurs in 5-8% of European-origin populations; similar rates are reported in Türkiye. It is thought to be an evolutionary advantage: carriers had better survival in hemorrhagic conditions of the middle ages (sepsis, trauma). Today this "advantage" becomes a problem combined with modern risk factors.
Heterozygous vs Homozygous
- Heterozygous (one gene copy mutated): The most common state. Lifetime thrombosis risk rises about 4-8 fold versus healthy individuals, but absolute annual risk remains low at 0.1-0.2%.
- Homozygous (both copies mutated): Risk can rise 20-80 fold with a markedly increased probability of at least one thrombotic event. Homozygous individuals need family screening and lifelong physician-guided planning.
When Does It Cause Problems?
FVL alone — especially without additional risk factors — is mostly silent. Risk rises sharply with: estrogen-containing contraceptives, pregnancy and postpartum, prolonged immobility (long flights, bed rest), surgery, obesity and smoking. Homozygosity or combined thrombophilia (e.g. FVL + Prothrombin mutation) multiplies risk.
How Is It Tested?
Testing uses a blood sample from an arm vein. After DNA isolation the FVL region is analyzed by PCR and real-time fluorescence. Results are reported as: normal (G/G), heterozygous (G/A), homozygous (A/A). When FVL is found in a family, screening first-degree relatives is recommended; the result directly affects family planning and hormone therapy decisions.
Recommendations for FVL Carriers
- Avoid estrogen-containing contraceptive pills; discuss progestin-based or non-hormonal alternatives with your physician.
- On long flights/journeys: plenty of water, regular walking, compression stockings if needed.
- Clarify prophylaxis plans with your physician for surgery and bed-rest periods.
- Maintain healthy weight, quit smoking.
- Seek preconception counseling if planning pregnancy.
Treatment
Carrier status itself needs no treatment; treatment is planned when thrombosis occurs or in high-risk situations. Heterozygous carriers who develop DVT/PE receive standard anticoagulation duration; extended therapy is considered for recurrent events or high-risk prophylaxis. Decisions always belong to the hematology specialist.
Conclusion
FVL is a genetic trait managed with knowledge. Even with a positive result, correct precautions allow a normal healthy life. If you have a family history, discuss testing with your physician.